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Implications for Existing Law/Regulations
Ellen Wright Clayton*
I just spent the last six months reviewing the
pharmacogenomics and pharmacogenetics literature. When you
read that literature there are an amazing number of claims made
about the relevance of race and ethnicity, that people in different
groups vary in the frequencies of pharmacogenetically relevant
alleles-alleles that influence the way you metabolize and
generally respond to drugs. These allele frequency differences will
or will not translate into phenotypic differences. Many, many
things influence the way people respond to drugs, and genes are
not always as important as many other factors. Nor do allelic
variations correlate easily with socially constructed categories of
race and ethnicity.
This controversy is not a huge issue for the HapMap because
the only thing that was collected about these individuals was their
gender and what part of the world they came from. There was no
phenotypic data at all. Moreover, at present it is not possible to
identify someone from their genotype. In order to do that, it is
necessary to have another genotype from them that you know is
theirs-that is how DNA identification works in the forensic
setting-or there has to be some existing genotype already on the
web with their name on it.
One pressing issue is whether just sequence data is considered
"identifying" data under HIPAA.' HIPAA establishes eighteen
categories of identifiers. 2 Removing those identifiers renders the
sample unidentified. However, some people argue that DNA
sequences may be the ultimate unique identifier under HIPAA and,
therefore, cannot be de-identified. I hope that the Department of
• Copyright 2005, by Louisiana Law Review.
M.D., J.D., Rosalind E. Franklin Professor of Genetics and Health
Policy, Director of Genetics and Health Policy Center, Senior Fellow, Institute
for Public Policy Studies, Professor of Law, Professor of Pediatrics, Vanderbilt
University. This work is based on a live presentation made on February 6, 2004,
and does not necessarily reflect events and changes thereafter.
1. See generally U.S. Dep't of Health and Human Services, Office for
Civil Rights, HIPAA, Medical Privacy, http://www.hhs.gov/ocr/hipaa (last
visited Aug. 26, 2005).
2. Id.
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Health and Human Services will address this issue and come to the
right decision: that this is not personally protected health
information under HIPAA. If it is, then certainly all genetics
research is going to come to a screeching halt.
There also are issues of individual remuneration. Note that the
word I am using is remuneration and not compensation. Lawyers
know that compensation usually means that you get something
because something bad happened to you.
Damages are
compensation. Remuneration is getting paid because you did
something. And the issue that we are debating both nationally and
internationally with regard to remuneration is, "what can be paid
for?" and whether the amount is sufficient or coercive. At least in
the United States, the rule tends to be that research participants can
be paid for inconvenience, for travel expenses, for things of that
nature, but may not, for example, be paid for risk. Not that there is
any particular risk in this research, but one cannot be paid for that.
On the other hand, in the employment context, risk can be
precisely what workers get paid for.' People who experience risk
in their jobs, all other things being equal, get paid more than
people who are not getting paid for risky jobs. Thus, ethical
issues remain.
In the international HapMap Project, new samples were
collected in Ibadan, Nigeria, the area around Tokyo, Japan, and
Beijing Normal University in China. The amount of money that
was contemplated was fifty U.S. dollars, which is not a very big
deal in Japan, but is a really big deal in Nigeria. One of the things
that people discussed was whether it was just to pay fifty U.S.
dollars in Nigeria or whether it was too coercive. Would it be
more appropriate to pay a smaller amount and then use the rest of
the money that would otherwise be spent for creating community
infrastructure? These issues are ones that apply to the HapMap
3. Peter Dorman & Paul Hagstrom, Wage CompensationFor Dangerous
Work Revisited, 52 Indus. & Lab. Rel. Rev. 116 (1998); Kip Viscusi, Job
Safety, The Concise Encyclopedia of Economics, available at http://www.
econlib.org/library/Enc/JobSafety.html (last visited Sept. 1, 2005); Mark
Aldrich, History of Workplace Safety in the United States, 1880-1970, EH.Net
Encyclopedia, http://www.eh.net/encyclopedia/?article=aldrich.safety.workplace
.US.

4.

Dorman & Hagstrom, supra note 3; Viscusi, supra note 3; Aldrich,

supranote 3.
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but, in point of fact, pervade all biomedical research throughout the
world. How do you apply standards justly and fairly in different
settings?
The bigger issues with regard to the HapMap have to do with
community interests. One of the issues is that descriptions tend to
become reified. As Professor Ossorio will address in some detail,
these are socially constructed categories. These populations do not
exist as distinct biological entities. More generally, it will be
necessary to attend to the possibility that finding particular genetic
variations to be more prevalent in one group than another may
prove stigmatizing.
For example, looking for a gene that
predisposes to alcoholism among populations that tend to have a
high rate of alcoholism is potentially stigmatizing. These are
issues that we confront head-on in the HapMap, even though there
is no particular desire, or even ability, to directly look and find
genes of interest with this particular tool.
Claims to benefits are another big issue. Do the groups from
which we collect samples have a claim to benefit? Is there
something that they ought to be getting back from this? This is
reminiscent of the claims of bio-piracy that were raised-whether
appropriately or not-in the context of the Human Genome
Diversity Project ("HGDP").
Sometimes, appearance and
perception matter. That was a major issue that afflicted the HGDP.
This issue also necessitates questioning whether research
should be conducted in resource-poor countries. One of the
complaints that has been raised about the effort to do this research,
to collect samples among the Yoruba in particular, is "How are
they going to benefit from this in the near term?" One answer is
that, in fact, nobody benefits from this in the near term. The hope
is that the HapMap will facilitate gene discovery. That is a
hypothesis, not an assumption. If the hypothesis turns out to be
true, that will be great. If the hypothesis turns out to be bad, then
that will be unfortunate. To return to the question, "Can we do this
sort of basic science research in resource poor countries?" it is
important to do this research in poor countries. Doing the HapMap
with only people of Northern European ancestry would be even
more profoundly unjust than trying to look throughout the world as
we try to figure out how to do gene discovery for health problems
that afflict all populations, not just those from Northern Europe.
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In doing this research, it is important to be attentive to cultural
and language differences. The idea of asking permission in a way
that we think is completely normative in the U.S. in 2004 is not
normative in many other parts of the world.
Negotiating
permission turns out to be a profoundly difficult ethical issue. The
ability to talk about genetics can be incredibly difficult, especially
when the potential subject does not have a word for "genetics" in
his or her language. However, many investigators have found that
all cultures have an idea about things running in families, so that is
a possible starting point.
If one is going to do research throughout the world, another
issue is capacity building. One has to make sure that study
populations not only benefit from the research, but also have the
capacity to undertake research that is relevant to their own
populations. The HapMap contributed to capacity building at the
outset in an administrative sense by putting mechanisms in place to
make sure that there is appropriate review by independent bodies
of the government and independent bodies of investigators who
actually look at the soundness of the research design, the quality of
the investigators, the appropriateness of procedural and security
provisions, and the adequacy of informed consent.
A foundational question for the HapMap project is, "Who has
access to the samples and under what conditions?" The decision
was made early on to store these in the Coriell-NIGMS Repository
in New Jersey. These samples will be made available to any
investigator throughout the world who has an Institutional Review
Board ("IRB")-approved protocol and who is approved by the
Coriell IRB. Moreover, the use of these samples is going to be
overseen by community advisory groups in all of these various
populations who will be apprised of the kind of research that is
being done, and who, if they choose, has the ability to remove
samples from the repository if they do not like the kind of research
that is being undertaken.
Now for a few words about intellectual property. One of the
things about the HapMap is that because it is a basic research tool,
because it has no clinically associated information, there is going
to be almost nothing to patent there. But one of the major ongoing
debates in genetics has been, "What do we do about protection of
intellectual property in genetics, and how is this really going to be
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made available?" We have heard some discussion, although I think not
nearly enough, about the issues with intellectual property in this area.
We all know about companies like Myriad which have
aggressively acted to protect their patents and to make sure nobody else
can do the testing. 5 We have also seen many other instances of
defensive patenting, where the goal is to make sure that things are
available on a reasonable basis. No clear model for that exists yet.
From the donors' perspective, the perspective of the people who
provide the DNA samples in the HapMap setting, there is no possibility
of sharing any intellectual property interest with these donors because
we do not know who they are. But, certainly, other groups like PXE
International which, I believe, Professor Malinowski talked about
before I arrived here yesterday, have explored other kinds of models
that allow some benefit sharing.
The main concern that many ofthese entities have is that they want
to make sure any resulting genetic tests associated with disease are
available on a reasonable basis. The consideration that they may not
fully take into account is that, unless there is some commercial benefit
to somebody somewhere, these products are not going to be brought to
market. In the context of the HapMap, a click-wrap agreement
basically said that people who use this data promise not to seek
6
intellectual property protection on it until they defined its utility.
In closing, this was a rather rapid romp through issues associated
with the HapMap, which have not been primarily legal thus far. The
issues have been political, social, and ethical. I hope that, in the
process, we have managed to learn some things about how better to
proceed in a way that creates trust with people who are going to be
involved in genetic epidemiology research as research participants. It
would be hubris to say that we have either gotten this right or that the
HapMap is going to be the be-all and end-all of tools. HapMap is a
step. It is a hypothesis. Let us hope it fulfills the vision.
5. Chemicon Enters Into Agreement with Myriad Genetics for Patented
Research Tools, Pharma Agreement News, Jan. 19, 2004, available at 2004
WLNR 293572; Nola M. Ries and Stacey E. Grubb, Patentsand Your Health,
Law Now, Jan. 1, 2004, availableat 2004 WLNR 61763.
6. Mapping of Human Genetic Variation Will Speed Searchfor Disease
Genes Haplotyping, Health & Medicine Week, Jan. 3, 2005, 2005 WLNR
10268; Life Science Weekly, Jan. 4, 2005, 2005 WLNR 11657; Medical Letter
on the CDC & FDA, Jan. 9, 2005, 2005 WLNR 13117; Genomics & Genetics
Weekly, Jan. 7, 2005, 2005 WLNR 9685.

